Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:MCUJF

Medicure Q1 2025 Earnings Results & Report

Medicure logo
$2.76 -0.04 (-1.43%)
As of 10/14/2026 03:58 PM Eastern

Medicure reported Q1 2025 earnings on May 21, 2025. The company reported EPS of -$0.05, while revenue was $3.82 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes

Medicure EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$3.82 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Q1 2025 Earnings FAQ

Medicure (OTCMKTS:MCUJF) reported earnings of -$0.05 per share for Q1 2025. The report was announced on Wednesday, May 21, 2025.

Medicure reported revenue of $3.82 million for Q1 2025.

Medicure's next earnings date is estimated for Thursday, November 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Medicure on the company's earnings history page.

Medicure Earnings Headlines

Medicure (OTCMKTS:MCUJF) Stock Crosses Above 50 Day Moving Average - What's Next?
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105044
MEDICURE : ANNOUNCES GRANT OF STOCK OPTIONS
October 1, 2026  |  marketscreener.comM
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
September 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69697627-medicure-inc-medicure-announces-completion-of-enrollment-in-its-mend-pnpo-phase-3-clinical-trial-200.htm
Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...
May 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/medicure-inc-mcujf-q1-2026-210021888.html
Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
May 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68566676-medicure-inc-medicure-reports-financial-results-for-quarter-ended-march-31-2026-and-schedules-may-25-2026-conference-call-200.htm
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company is headquartered in Winnipeg, Manitoba, and has concentrated its commercial activities on products intended for use in hospital and acute-care settings.

Medicure’s principal product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the management of certain patients with acute coronary syndrome and other cardiovascular conditions. The product is designed to inhibit platelet aggregation and is marketed primarily through Medicure’s U.S. operations, with the company also pursuing opportunities in other markets where appropriate.

Medicure has historically maintained a focus on cardiovascular drug development, commercialization, and licensing. The company is led by Dr. Albert D. Friesen, who has served as its president and chief executive officer. Medicure’s shares trade in Canada and in the United States under the symbol MCUJF.

View Medicure Profile
Earnings Tools